About This Comparison
Our Editorial Standards
This hair loss provider comparison is independently researched by our editorial team. We compare telehealth services based on publicly available information including pricing, available treatments, and service areas. Our ratings are editorial judgments, not tallies of reviews.
Independent Research: We do not accept payment for rankings or favorable reviews
Affiliate Disclosure: We may earn commissions from qualifying purchases at no extra cost to you
Regular Updates: Content is reviewed and updated monthly for accuracy
Licensed Providers Only: All listed services employ US-licensed healthcare providers
Not Medical Advice: This comparison is for informational purposes only. We are not healthcare providers. Always consult with a licensed physician before starting any treatment. Read our full medical disclaimer and editorial policy.
Independent ResearchNo paid placements
Fact-Checked InformationVerified against official sources
Regularly UpdatedLast updated September 11, 2026
Licensed Providers OnlyAll listed services are US-licensed
Finasteride for Women
Finasteride has no FDA approval for hair loss in women, so every prescription is off-label, and it is contraindicated if you are or may become pregnant. The evidence splits hard by dose. In the only placebo-controlled trial, 137 postmenopausal women took 1 mg daily for 12 months and ended with no significant difference in hair count against placebo. The 2.5 mg and 5 mg support is thinner but looks better.
How Finasteride Works in Women
Finasteride is a competitive inhibitor of the type II and type III forms of 5-alpha-reductase, the enzyme that turns testosterone into dihydrotestosterone. Less DHT reaching a follicle means less of the miniaturization that shrinks a thick terminal hair into a wispy one. In male pattern hair loss that single pathway carries most of the disease, which is why a 1 mg tablet does real work there. Female pattern hair loss shares the name and only part of the biology.
Scalp biopsies from 12 women and 12 men aged 18 to 33 show where the two diverge. Women's frontal follicles held about three times less type I and 3.5 times less type II 5-alpha-reductase than men's, six times more aromatase, and roughly 40 percent less androgen receptor. There is less DHT machinery for finasteride to shut down, and more testosterone being converted into estrogen before it ever becomes DHT. That is the honest reason this drug does not travel cleanly across sexes.
- Blocks 5-alpha-reductase, cutting the conversion of testosterone into DHT
- Women's frontal follicles carry roughly three times less of that enzyme than men's
- Six times more aromatase in those follicles routes testosterone toward estrogen instead
- Less DHT machinery to switch off leaves the drug less to do
Does Finasteride Work for Female Hair Loss?
The dose is the whole story, more than menopausal status is. In 137 postmenopausal women aged 41 to 60 randomized to finasteride 1 mg daily or placebo for a year, there was no significant difference in hair count change, and both groups lost hair count across the frontal and parietal scalp. Self-assessment, investigator assessment, blinded photograph panels and scalp biopsies all found nothing. The FDA label carries that result in its own words: effectiveness could not be demonstrated. Push the dose and the picture inverts. A network meta-analysis of 13 trials in adult women ranked 5 mg daily for 24 weeks first of ten regimens (SUCRA 95.7 percent), 5 percent topical minoxidil solution twice daily second (89.5 percent), and 1 mg daily dead last (4.3 percent). Same molecule, opposite ends of one ranking. The catch is evidence quality: an earlier network of 10 female randomized trials could rank only laser therapy, 5 percent minoxidil and 2 percent minoxidil, because no finasteride trial in women qualified for it.
- 1 mg failed the only placebo-controlled trial ever run in women
- A network meta-analysis ranked 5 mg first and 1 mg last out of ten regimens
- Every positive finasteride result in women comes from open-label or chart-review work
- No dose has been tested against placebo in premenopausal women
Why Finasteride Is Contraindicated in Pregnancy
This is not a caution, it is a contraindication, and it comes before any conversation about hair. Finasteride use is contraindicated in women when they are or may potentially be pregnant, because inhibiting the conversion of testosterone to DHT may cause abnormalities of the external genitalia of a male fetus.
In pregnant rats dosed through organogenesis, the same label records a dose-dependent increase in hypospadias affecting 3.6 to 100 percent of male offspring across roughly 1 to 684 times the 1 mg human dose.
The handling rule carries as much weight as the swallowing rule. The tablets are film-coated, and the label states the coating prevents contact with the active ingredient during normal handling only if the tablet has not been broken or crushed; if contact does happen, wash the area immediately with soap and water. That matters here more than on the men's page, because the cheapest route to an off-label 2.5 mg dose is splitting a 5 mg tablet, which destroys the barrier the label depends on.
- Contraindicated if you are pregnant or may potentially become pregnant
- Blocking DHT can affect how a male fetus's external genitalia develop
- Never handle a crushed or broken tablet; the intact coating is the barrier
- Halving a 5 mg tablet to reach 2.5 mg breaks exactly that coating
Whose Hair Loss This Is Considered For
Two signals in the published series point the same way: earlier and milder loss responds better. In a chart review of 112 women prescribed 2.5 mg daily, response was stronger in those with a lower Ludwig grade and an older age at onset, and in 40 postmenopausal women on 5 mg daily for 18 months, older age tracked with worse response. Nobody in this literature was rescued from an advanced, long-standing pattern, so timing is part of the decision.
Diagnosis matters more than dose here. The strongest randomized evidence for finasteride in women is not in pattern hair loss at all: 34 women with frontal fibrosing alopecia, a scarring alopecia, were randomized to finasteride 2.5 mg daily or hydroxychloroquine 400 mg daily for six months, and both groups improved on severity and trichoscopy scores with no significant difference between them. If your loss is scarring, patterned, or a telogen effluvium, those are three different answers.
- Settled contraception, or menopause, is the entry condition rather than a footnote
- Diffuse widening at the part with a preserved hairline is the target pattern
- Thyroid, iron and postpartum causes get ruled out before any tablet
- Scarring hair loss is a different disease with different evidence
Finasteride Against Minoxidil, Spironolactone and Dutasteride
Two treatments hold FDA approval for pattern baldness, topical minoxidil and finasteride, but finasteride's approval is for men only, and oral antiandrogens such as spironolactone are what get used off-label in women instead. That sets a normal sequence: topical minoxidil first because it is the approved option, then spironolactone, then a 5-alpha-reductase inhibitor.
Our separate pages on minoxidil for women and spironolactone for hair loss cover those two steps in full.
Head to head, the gap is smaller than the ranking suggests. In postmenopausal women followed for 12 months on oral finasteride 2.5 mg, topical finasteride 0.25 percent solution, or topical minoxidil 5 percent twice daily, oral finasteride ranked highest and topical finasteride lowest across four endpoints, but none of the differences reached statistical significance. Dutasteride is roughly three times more potent against the type II enzyme and 100 times more potent against type I, with a half-life of weeks rather than hours.
- Topical minoxidil is the only pattern hair loss treatment carrying approval for women
- Spironolactone blocks the androgen receptor rather than the enzyme upstream of it
- Dutasteride hits the type I enzyme around 100 times harder and lingers for weeks
- Oral finasteride edged both topical options in one cohort, without statistical significance
Finasteride Dosage for Women
At 2.5 mg the best-known series bundled in a hormonal confound. Thirty-seven premenopausal women took finasteride 2.5 mg daily alongside an oral contraceptive containing drospirenone and ethinyl estradiol for 12 months; 23 improved on global photography and hair density rose significantly in 12 (p=0.002). The authors said plainly they could not tell whether the higher dose or the drospirenone, itself antiandrogenic, produced the result. Read that 62 percent as a combination figure, not a finasteride figure.
At 5 mg the numbers are larger and still uncontrolled. Eighty-seven normoandrogenic women, both premenopausal and postmenopausal, took 5 mg daily for 12 months: hair density rose from 90 to 107 hairs per square centimeter (P<0.001), thickness from 64 to 70 microns (P=0.02), and 81.4 percent improved on global photographs. There was no placebo arm. Finasteride's serum half-life is 5 to 6 hours, which is a fact about the drug rather than a clearance instruction; ask your clinician about timing around any pregnancy plan.
- Tablets are manufactured at 1 mg and 5 mg only, so 2.5 mg is not a stock strength
- Published off-label regimens run 1 mg, 2.5 mg and 5 mg once daily
- Studies ran 6 to 18 months before calling a result either way
- Half-life is 5 to 6 hours, so the drug itself clears quickly once stopped
Side Effects and What Gets Checked
The reported burden in women is modest but the denominators are small. Across 87 women on 5 mg daily, four (4.6 percent) reported adverse events, namely headache, menstrual irregularity, dizziness and increased body hair growth, all mild and short-lived, with one withdrawal for headache. In the separate 18-month series of 40 postmenopausal women, four described a sustained drop in libido and one showed a rise in liver enzymes. Report a menstrual change rather than waiting it out.
On the mood question, the large data exists but does not answer it for you. A meta-analysis of five studies with a combined cohort of 2,213,600 found no statistically significant association between 5-alpha-reductase inhibitor exposure and depression (adjusted hazard ratio 1.30, 95 percent CI 0.85 to 2.00) or suicide (1.30, 95 percent CI 0.65 to 2.61).
Those cohorts are overwhelmingly men treated for prostate enlargement or male pattern loss, so it is reassurance about the drug class rather than about this off-label use.
- Menstrual irregularity, headache, dizziness and extra body hair were the reported events
- Reduced libido persisted for four women across an 18-month series
- One liver enzyme rise in that same series; finasteride is cleared through the liver
- No routine lab schedule is mandated, so monitoring gets set case by case
Getting Finasteride Prescribed Online
Because finasteride is not indicated for use in women, no telehealth service can hand it over as a routine refill of an approved product. A consultation worth paying for asks about pregnancy plans and contraception, menopausal status, family history, and the thyroid, iron and postpartum causes that mimic pattern loss. An intake form that never raises pregnancy is a reason to stop, whatever it saves you in time.
Finasteride is normally added to a routine rather than swapped in for one. Both arms of the frontal fibrosing alopecia trial ran topical minoxidil alongside the oral drug, and the 2.5 mg chart review deliberately excluded anyone using topical minoxidil, which is precisely why its 65.2 percent significant-improvement figure reads as a monotherapy number. Our general finasteride page covers the male-approved use this one deliberately does not repeat.
- Off-label prescribing is lawful, which puts the whole weight on the consultation
- Expect questions about pregnancy plans, contraception and menstrual history
- Most published protocols keep topical minoxidil running underneath
- Baseline photographs are the only honest way to judge a slow change
How Much Finasteride Costs
The drug itself is close to free at wholesale. Medicaid's national average drug acquisition cost, in the file published on 2 September 2026, is $0.04260 per 1 mg finasteride tablet and $0.06839 per 5 mg tablet, both classified generic. That is a 30 day supply of 5 mg for roughly $2.05 in acquisition cost. We do not publish a single retail figure, because acquisition cost is a floor and pharmacy markup, dispensing fees and any telehealth consultation or subscription sit on top of it and vary widely.
The insurance answer follows from the label rather than from your plan. The approved indications for finasteride are male pattern hair loss and benign prostatic hyperplasia, so a claim written for female pattern hair loss is off-label and commonly denied.
One more cost trap worth naming: reaching 2.5 mg by halving a 5 mg tablet is the cheapest arithmetic on this page and it is the exact scenario the broken-tablet handling warning exists for.
- Pharmacy acquisition cost is 4.26 cents for a 1 mg tablet
- A 5 mg tablet runs 6.84 cents, about $2.05 for a 30 day supply
- Acquisition cost is what pharmacies pay, before the markup you get charged
- Off-label use makes insurance coverage unlikely, so budget it as cash
Picking a Clinician for an Off-Label Hair Plan
Judge the consultation, not the branding. A clinician comfortable with this drug in women should be able to say which dose they use and why, should know that the 1 mg evidence is negative, and should treat the pregnancy contraindication as a gate rather than a disclaimer at checkout. Ask what happens if you want to conceive later, and whether they will keep prescribing without a review point.
Look for standardized baseline photographs, a stated month at which the plan gets judged, and a written sequence that starts with the approved topical option. None of this is medical advice, and the prescribing decision belongs to a clinician who knows your history.
Consistent use for at least four to six months is needed before change becomes visible in pattern hair loss, so anyone promising a faster verdict is selling something else.
- Ask which dose they use in women and what evidence they are working from
- Insist on a diagnosis before a prescription rather than alongside it
- Contraception belongs in the first conversation
- Standardized photographs and a fixed review date beat vague reassurance
Frequently Asked Questions
Is finasteride approved for women?
The FDA label states that finasteride 1 mg is indicated for male pattern hair loss in men only and is not indicated for use in women. So no, it is not approved for women. Any prescription written for female pattern hair loss is off-label, which is lawful but means the dose, the monitoring and the risk conversation all rest on your clinician's judgment rather than on an approved regimen.
Does the 1 mg dose work for female pattern hair loss?
The only placebo-controlled trial says no. Among 137 postmenopausal women taking 1 mg daily for 12 months, there was no significant difference in hair count against placebo, and hair count fell in both groups. A later network meta-analysis ranked 1 mg last of ten regimens studied in women. Higher doses look better, but only in studies without a placebo arm.
Can you take finasteride if you might become pregnant?
No. Finasteride is contraindicated in women who are or may potentially be pregnant, because reducing DHT may cause abnormalities of the external genitalia of a male fetus. The same label tells women who are or may become pregnant not to handle a crushed or broken tablet at all, since the film coating is what prevents skin contact with the active ingredient.
Should you try spironolactone or finasteride first?
Neither is FDA-approved for hair loss in women, so the sequence is a clinical judgment rather than a rule. Topical minoxidil is the option that carries approval, and spironolactone is the oral antiandrogen most commonly used off-label in women. Finasteride usually enters after those, so our spironolactone for hair loss page sits earlier in the same sequence.
How long before you know whether it is working?
Pattern hair loss treatments need at least four to six months of consistent use before change is visible, and the studies in women ran 12 to 18 months. In one 18-month series the gain from month six onward was slight, so a fair review point is somewhere between six and twelve months with standardized photographs taken at the start.
Is topical finasteride a workaround for the pregnancy warning?
Nothing in the published comparisons supports treating it that way. In the postmenopausal cohort that compared oral finasteride, topical finasteride 0.25 percent and topical minoxidil, the topical finasteride arm ranked lowest of the three, with no significant difference between arms. The contraindication attaches to the molecule, so raise any pregnancy plan with your clinician before considering any formulation.
Sources & References
Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.
- a competitive inhibitor of the type II and type III forms of 5-alpha-reductase
- Women's frontal follicles held about three times less type I and 3.5 times less type II 5-alpha-reductase than men's, six times more aromatase, and roughly 40 percent less androgen receptor
- In 137 postmenopausal women aged 41 to 60 randomized to finasteride 1 mg daily or placebo for a year, there was no significant difference in hair count change, and both groups lost hair count across the frontal and parietal scalp
- The FDA label carries that result in its own words: effectiveness could not be demonstrated
- A network meta-analysis of 13 trials in adult women ranked 5 mg daily for 24 weeks first of ten regimens (SUCRA 95.7 percent), 5 percent topical minoxidil solution twice daily second (89.5 percent), and 1 mg daily dead last (4.3 percent)
- an earlier network of 10 female randomized trials could rank only laser therapy, 5 percent minoxidil and 2 percent minoxidil
- The tablets are film-coated, and the label states the coating prevents contact with the active ingredient during normal handling only if the tablet has not been broken or crushed
- In a chart review of 112 women prescribed 2.5 mg daily, response was stronger in those with a lower Ludwig grade and an older age at onset
- in 40 postmenopausal women on 5 mg daily for 18 months, older age tracked with worse response
- 34 women with frontal fibrosing alopecia, a scarring alopecia, were randomized to finasteride 2.5 mg daily or hydroxychloroquine 400 mg daily for six months, and both groups improved on severity and trichoscopy scores with no significant difference between them
- Two treatments hold FDA approval for pattern baldness, topical minoxidil and finasteride, but finasteride's approval is for men only, and oral antiandrogens such as spironolactone are what get used off-label in women instead
- In postmenopausal women followed for 12 months on oral finasteride 2.5 mg, topical finasteride 0.25 percent solution, or topical minoxidil 5 percent twice daily, oral finasteride ranked highest and topical finasteride lowest across four endpoints, but none of the differences reached statistical significance
- Thirty-seven premenopausal women took finasteride 2.5 mg daily alongside an oral contraceptive containing drospirenone and ethinyl estradiol for 12 months; 23 improved on global photography and hair density rose significantly in 12 (p=0.002)
- Eighty-seven normoandrogenic women, both premenopausal and postmenopausal, took 5 mg daily for 12 months: hair density rose from 90 to 107 hairs per square centimeter (P<0.001), thickness from 64 to 70 microns (P=0.02), and 81.4 percent improved on global photographs
- A meta-analysis of five studies with a combined cohort of 2,213,600 found no statistically significant association between 5-alpha-reductase inhibitor exposure and depression (adjusted hazard ratio 1.30, 95 percent CI 0.85 to 2.00) or suicide (1.30, 95 percent CI 0.65 to 2.61)
- Medicaid's national average drug acquisition cost, in the file published on 2 September 2026, is $0.04260 per 1 mg finasteride tablet and $0.06839 per 5 mg tablet, both classified generic
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards